Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonigutamab - Pierre Fabre/ACELYRIN

Next Previous
X
Search
Drug Profile

Lonigutamab - Pierre Fabre/ACELYRIN

Alternative Names: anti-IGF-1R monoclonal antibody - ACELYRIN; VB-421

Latest Information Update: 21 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pierre Fabre
  • Developer ACELYRIN
  • Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action IGF type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graves ophthalmopathy
  • Preclinical Inflammation

Most Recent Events

  • 13 Nov 2024 ACELYRIN attends an End-of-phase II meeting with the US FDA for phase III trial in Graves ophthalmopathy before November 2024
  • 16 Oct 2024 ACELYRIN completes a phase-I/II trial in Graves ophthalmopathy in Australia and USA (SC), , (NCT05683496)
  • 16 Oct 2024 ACELYRIN plans a phase-III trial for Graves ophthalmopathy in the first quarter of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top